Red Blood Cell Alloimmunization after Blood Transfusion

Schonewille, Henk

doi:10.5117/9789087280314

Cited by 8 publications

(6 citation statements)

References 246 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although 'K' seconds 'D' in antigenicity [30] and has been found to be the the most frequent alloantibody [2,19] in few previous studies, none of our 13 (5.3 %) patients exposed to 'K' antigen developed anti-K. This is in accordance to Schonewille's [33] observation that for developing an antibody against 'K' multiple transfusions are required. He also observed that the predominant antibody formed after 5 years of transfusion were anti-K and anti-Fy a .…”

Section: Immunological Response To Antigenic Exposuressupporting

confidence: 90%

Rh and Kell Phenotype Matched Blood Versus Randomly Selected and Conventionally Cross Matched Blood on Incidence of Alloimmunization

Makroo

Agrawal

Chowdhry

2016

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

There is paucity of literature regarding efficacy of transfusion of Rh and Kell matched blood in reducing alloimmunization risk among non-chronically transfused patients. A prospective study to compare efficacy of Rh and Kell phenotype matched blood over randomly selected and conventionally cross-matched blood on the incidence of alloimmunization in patients undergoing cardiac surgery was carried out in the Department of Transfusion Medicine at Indraprastha Apollo Hospitals, New Delhi, from 1st September, 2013 to 31st December, 2014. Two groups, A and B of 250 each were studied. Group A received ABO, Rh and Kell phenotype matched units. Group B received units matched only for ABO and Rh D. Retrospective analysis for antigenic exposures was done. Alloimmunization rate was evaluated for both groups after 72 h and 4 weeks and compared. A value ≤0.05 was considered statistically significant. None of the patients in Group A were alloimmunized. In Group B, 119 patients received antigenic stimulus (single antigen stimuli- 93; multiple- 26). The probability of a patient being exposed was 52.4 %. At 6 weeks post transfusion, one patient developed 'Anti-E' and had received 'E' stimulus once. The rate of alloimmunization was 0.4 % in group B, 0.8 % overall and the risk of alloimmunization per unit transfused was 0.17 %. Non responders were 99.16 %. The study did not reach statistical significance ( = 0.238). Majority of our population are non-responders therefore, the resources and time can be reserved for providing Rh and Kell matched units for multiply transfused patients.

show abstract

Section: Immunological Response To Antigenic Exposuressupporting

confidence: 90%

Rh and Kell Phenotype Matched Blood Versus Randomly Selected and Conventionally Cross Matched Blood on Incidence of Alloimmunization

Makroo

Agrawal

Chowdhry

2016

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

show abstract

“…In other specialties alloimmunization rate ranged from 0.7 to 1.0%. In a similar study, Schonewille also reported that occasionally transfused patients have alloimmunization rate ranging between 1 and 3% [ 19 ]. The most prevalent antibodies in our study were against E (36.3%), D (16.0%), and c (6.4%) and c + E (6.4%), C + D (5.1%), and K (4.5%) antigens.…”

Section: Discussionmentioning

confidence: 99%

Prevalence and Specificity of RBC Alloantibodies in Indian Patients Attending a Tertiary Care Hospital

Zaman

Chaurasia

Chatterjee

et al. 2014

Advances in Hematology

View full text Add to dashboard Cite

Background. Red blood cell (RBC) alloimmunization results from genetic disparity of RBC antigens between donor and recipients. Data about alloimmunization rate in general patient population is scarce especially from resource limited countries. We undertook this study to determine prevalence and specificity of RBC alloantibodies in patients admitted in various clinical specialties at a tertiary care hospital in North India. Methods. Antibody screening was carried out in 11,235 patients on automated QWALYS 3 platform (Diagast, Loos, France). Antibody identification was carried out with an 11-cell identification panel (ID-Diapanel, Diamed GmbH, Switzerland). Results. The overall incidence of RBC alloimmunization in transfused patients was 1.4% (157/11235), with anti-E being the most common specificity (36.3%), followed by anti-D (16%), anti-c (6.4%), anti-c + E (6.4%), anti-C + D (5.1%), and anti-K (4.5%). The highest incidence of alloimmunization was observed in hematology/oncology patients (1.9%), whereas in other specialties the range was 0.7–1%. Conclusion. As alloimmunization complicates the transfusion outcomes, authors recommend pretransfusion antibody screening and issue of Rh and Kell matched blood to patients who warrant high transfusion requirements in future.

show abstract

“…The current debates are framed by the interim and final reports of a commission that reviewed the DCCP and the spin-off of those reports (Asser et al 2003(Asser et al , 2006Tzankova 2007c). 31 The current debates concern mainly (1) funding, 32 (2) whether collective actions for damages should be allowed under certain conditions, (3) the need for an "adequacy of representation" test for the class lawyers, (4) how to handle individually non viable claims (Tzankova 2005), and ( 5) the recent developments at the EU level (consumer and antitrust). Much thought is also being given to the question of how to ensure and enhance fair and reasonable collective settlements under the WCAM.…”

Section: Temporary Concerns and Issuesmentioning

confidence: 99%